Histone deacetylase inhibitors

• YOO CB, JONES PA: Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. (2006) 5:37-50.
   PubMed Web of Science ®Google Scholar
• INCHE AG, LA THANGUE NB: Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov. Today (2006) 11:97-108.
   PubMedGoogle Scholar
• LIN H-Y, CHEN C-S, LIN S-P: Targeting histone deacetylase in cancer therapy. Med. Res. Rev. (2006) 26:397-413.
   PubMed Web of Science ®Google Scholar
• JOHNSTONE RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. (2002) 1:287-299.
   PubMed Web of Science ®Google Scholar
• BOLDEN JE, PEART MJ, JOHNSTONE RW: Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. (2006) 5:769-784.
   PubMed Web of Science ®Google Scholar
• KRISTELEIT R, STIMSON L, WORKMAN P et al.: Histone modification enzymes: novel targets for cancer drugs. Expert Opin. Emerg. Drugs (2004) 9:135-154.
   PubMedGoogle Scholar
• CAREY N, LA THANGUE NB: Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol. (2006) 6:369-375.
   PubMed Web of Science ®Google Scholar
• MAI A, SILVIO M, ROTILI D et al.: Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J. Med. Chem. (2006) 49:6046-6056.
   PubMedGoogle Scholar
• WEINMANN E, OTTOW E: Histone deacetylase inhibitors: a survey of recent patents. Expert Opin. Ther. Patents (2005) 15:1677-1690.
   Web of Science ®Google Scholar
• MILLER TA: Patent status of histone deacetylase inhibitors. Expert Opin. Ther. Patents (2004) 14:791-804.
   Web of Science ®Google Scholar
• CURTIN ML: Current patent status of histone deacetylase inhibitors. Expert Opin. Ther. Patents (2002) 12:1375-1384.
   Web of Science ®Google Scholar
• ROSATO RR, GRANT S: Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs (2004) 13:21-38.
   PubMed Web of Science ®Google Scholar
• MARKS PA, DOKMANOVIC M: Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs (2005) 14:1497-1511.
   PubMed Web of Science ®Google Scholar
• KELLY WK, O'CONNOR OA, KRUG LM et al.: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. (2005) 23:3923-3931.
   PubMed Web of Science ®Google Scholar
• O'CONNOR OA, HEANEY ML, SCHWARTZ L: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. (2006) 24:116-173.
   Google Scholar
• KELLY WK, RICHON VM, O'CONNOR O: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intraveneously. Clin. Cancer Res. (2003) 9:3578-3588.
   PubMed Web of Science ®Google Scholar
• KELLAND L: Discontinued drugs in 2005: oncology drugs. Expert Opin. Investig. Drugs (2006) 15:1309-1318.
   PubMed Web of Science ®Google Scholar
• PRICE S, BORDOGNA W, BRAGANZA R et al.: Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett. (2007) 15:363-369.
   Google Scholar
• PRICE S, BORDOGNA W, BULL RJ et al.: Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett. (2007) 15:370-375.
   Google Scholar
• SUZUKI T, KOUKETSU A, MATSUURA A et al.: Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:3313-3317.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, NAGANO Y, KOUKETSU A et al.: Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J. Med. Chem. (2005) 48(4):1019-1032.
   PubMedGoogle Scholar
• SUZUKI T, MATSUURA A, KOUKETSU A et al.: Identification of a potent non-hydroxamate histone deactylase inhibitor by mechanism-based drug design. Bioorg. Med. Chem. Lett. (2005) 15:331-335.
   PubMedGoogle Scholar
• CHEN B, PETUKHOV PA, JUNG M et al.: Chemistry and biology of mercaptoamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:1389-1392.
   PubMed Web of Science ®Google Scholar
• AANADAN S-K, WARD JS, BROKX RD et al.: Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:1969-1972.
   PubMedGoogle Scholar
• SIEBURTH SM, CHEN C-A: Silanediol protease inhibitors: from conception to validation. Eur. J. Org. Chem. (2006) 2:311-322.
   Google Scholar
• FARACO G, TRISTANO P, FORMENTINI L et al.: Pharmacological inhibition of histone deactylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Phamacol. (2006) 70(6):1876-1884.
   PubMed Web of Science ®Google Scholar
• DE BOER J, LICHT R, BONGERS M et al.: Inhibition of histone acetylation as a tool in bone tissue engineering. Tissue Eng. (2006) 12(10):2927-2937.
   PubMedGoogle Scholar
• LEE HW, SUH JH, KIM AY et al.: Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol. Endocrinol. (2006) 20(10):2432-2443.
   PubMed Web of Science ®Google Scholar
• OKAMOTO H, TAKAHASHI A, TAKAHASHI T et al.: Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21WAF1. J. Atheroscler. Thromb. (2006) 13(4):183-191.
   PubMed Web of Science ®Google Scholar
• LENG C, GRIES M, ZIEGLER J et al.: Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp. Hematol. (2006) 34(6):776-787.
   PubMed Web of Science ®Google Scholar
• STEFFAN JS, BODAL L, PALLOS J et al.: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature (2001) 413(6857):739-743.
   PubMed Web of Science ®Google Scholar
• HOCKLY E, RICHON VM, WOODMAN B et al.: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. PNAS (2003) 100(4):2041-2046.
   PubMedGoogle Scholar
• SADRI-VAKili G, CHA J-HJ: Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr. Alzheimer Res. (2006) 3(4):403-408.
   PubMedGoogle Scholar
• HAHNEN E, EYUEPOGLU IY, BRICHTA L et al.: In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. (2006) 98(1):193-202.
   PubMed Web of Science ®Google Scholar
• SIMONINI MV, CAMARGO LM, DONG E et al.: The benzamide SNDX-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. PNAS (2006) 103(5):1587-1592.
   PubMed Web of Science ®Google Scholar

Patents

• MERCK & CO., INC.: WO2006017215 (2006).
   Google Scholar
• MERCK & CO., INC.: WO2006017216 (2006).
   Google Scholar
• MERCK & CO., INC.:WO2006026260 (2006).
   Google Scholar
• MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA: WO2006097449 (2006).
   Google Scholar
• MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA: WO2006097460 (2006).
   Google Scholar
• JOHNS HOPKINS UNIV.; WAYNE STATE UNIV.: WO2006113606 (2006).
   Google Scholar
• SK CORPORATION: WO2006075888 (2006).
   Google Scholar
• ASTELLAS PHARMA, INC.: WO2006016680 (2006).
   Google Scholar
• ASTELLAS PHARMA, INC.: US052599 (2006).
   Google Scholar
• ALTANA PHARMA AG: WO2005087724 (2005).
   Google Scholar
• ALTANA PHARMA AG: WO2006097474 (2006).
   Google Scholar
• ALTANA PHARMA AG: WO2006105979 (2006).
   Google Scholar
• S*BIO PTE LTD: WO2006101455 (2006).
   Google Scholar
• S*BIO PTE LTD: WO2006101456 (2006).
   Google Scholar
• S*BIO: WO2005028447 (2005).
   Google Scholar
• S*BIO: WO2005040101 (2005).
   Google Scholar
• DAC SRL: WO2006037761 (2006).
   Google Scholar
• SYRRX: WO2005065681 (2005).
   Google Scholar
• TAKEDA SAN DIEGO, INC.: US7154002 (2006).
   Google Scholar
• F HOFFMANN-LA ROCHE AG: WO2005121134 (2005).
   Google Scholar
• F HOFFMANN-LA ROCHE AG: WO2005121120 (2005).
   Google Scholar
• HOFFMANN-LA ROCHE LTD: WO2003011851 (2003).
   Google Scholar
• MERCK & CO., INC.: WO2006115835 (2006).
   Google Scholar
• MERCK & CO., INC.: WO2006115833 (2006).
   Google Scholar
• ATON PHARMA, INC.: WO2005034880 (2005).
   Google Scholar
• S*BIO PTE LTD: WO2006101454 (2006).
   Google Scholar
• ARGENTA DISCOVERY LTD: WO2005075469 (2005).
   Google Scholar
• ARGENTA DISCOVERY LTD: WO2004013130 (2004).
   Google Scholar
• ARGENTA DISCOVERY LTD: WO2005014588 (2005).
   Google Scholar
• CHROMA THERAPEUTICS LTD: WO2006123121 (2006).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2006010750 (2006).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2006010749 (2006).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2003075929 (2003).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2003076395 (2003).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2003076400 (2003).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2003076401 (2003).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2003076421 (2003).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2003076422 (2003).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2003076430 (2003).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2003076438 (2003).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2006122926 (2006).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2006136553 (2006).
   Google Scholar
• AXYS PHARMACEUTICALS, INC.: WO2005097770 (2005).
   Google Scholar
• AXYS PHARMACEUTICALS, INC.: US227976 (2005).
   Google Scholar
• AXYS PHARMACEUTICALS, INC.: WO2003066579 (2003).
   Google Scholar
• AXYS PHARMACEUTICALS, INC.: WO2004092115 (2004).
   Google Scholar
• AXYS PHARMACEUTICALS, INC.: WO2005019174 (2005).
   Google Scholar
• MERCK & CO., INC.: WO2006/017214 (2006).
   Google Scholar
• KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY AND CRYSTALGNOMICS, INC.: WO2006025683 (2006).
   Google Scholar
• ENVIVO PHARMACEUTICALS, INC.: WO2005108367 (2005).
   Google Scholar
• MIIKANA THERAPEUTICS, INC.: WO2006088949 (2006).
   Google Scholar
• MIIKANA THERAPEUTICS: US0250784 (2005).
   Google Scholar
• MIIKANA THERAPEUTICS: WO2005086898 (2005).
   Google Scholar
• ANANDAN SK, XIAO Z-Y, PATEL DV, WARD JS: US0234033 (2005).
   Google Scholar
• CHROMA THERAPEUTICS LTD: WO2006117548 (2006).
   Google Scholar
• CHROMA THERAPEUTICS LTD: WO2006117549 (2006).
   Google Scholar
• METHYLGENE, INC.: WO2005092899 (2005).
   Google Scholar
• METHYLGENE, INC.: US20050288282 (2005).
   Google Scholar
• ASTRAZENECA UK LIMITED: WO2006064246 (2006).
   Google Scholar
• ASTRAZENECA UK LIMITED: WO03087057 (2003).
   Google Scholar
• ASTRAZENECA UK LIMITED: WO03092686 (2003).
   Google Scholar
• ASTRAZENECA UK LIMITED: WO2006075160 (2006).
   Google Scholar
• ASTRAZENECA UK LIMITED: WO2006077387 (2006).
   Google Scholar
• TAKEDA SAN DIEGO, INC.: WO2006066133 (2006).
   Google Scholar
• TAKEDA SAN DIEGO, INC.: WO2006122319 (2006).
   Google Scholar
• MERCK & CO., INC. AND ATON PHARMA, INC.: WO2006115845 (2006).
   Google Scholar
• UNIVERSITY OF LEEDS: WO2005121073 (2005).
   Google Scholar
• KALYPSYS, INC.: WO2005120515 (2005).
   Google Scholar
• KALYPSYS, INC.: WO2006063294 (2006).
   Google Scholar
• KALYPSYS, INC.: WO2005123089 (2005).
   Google Scholar
• ARGENTA DISCOVERY LIMITED: WO2005075466 (2005).
   Google Scholar
• OSI PHARMACEUTICALS, INC.: WO2006028972 (2006).
   Google Scholar
• NIPPON KAYAKU CO. LIMITED: JP2005272419 (2005).
   Google Scholar
• UNIVERSITY OF SOUTHAMPTON: WO2006129105 (2006).
   Google Scholar
• AXYS PHARMACEUTICALS, INC.: WO2006069096 (2006).
   Google Scholar
• METHYLGENE, INC.: WO2006/102760 (2006).
   Google Scholar
• ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA AND MERCK & CO., INC.: WO2006005941 (2006).
   Google Scholar
• ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA AND MERCK & CO., INC.: WO2006005955 (2006).
   Google Scholar
• ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA: WO2006061638 (2006).
   Google Scholar